Long‐term safety and efficacy of SGLT2 inhibitor use in older east Asians with type 2 diabetes
Sodium‐glucose cotransporter 2 inhibitors (SGLT2is) have been shown in cardiovascular outcome trials to reduce the risk of heart failure and major adverse cardiovascular as well as renal events in individuals with type 2 diabetes. Moreover, clinical evidence indicates that SGLT2i use reduces heart f...
Main Authors: | Yoshihiro Takahashi, Yutaka Seino, Daisuke Yabe |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2024-01-01
|
Series: | Journal of Diabetes Investigation |
Online Access: | https://doi.org/10.1111/jdi.14097 |
Similar Items
-
Efficacy and Safety of the Use of SGLT2 Inhibitors in Patients on Incremental Hemodialysis: Maximizing Residual Renal Function, Is There a Role for SGLT2 Inhibitors?
by: José C. De La Flor, et al.
Published: (2023-07-01) -
Efficacy and safety of once‐weekly semaglutide in Japanese individuals with type 2 diabetes by baseline age and body mass index
by: Daisuke Yabe, et al.
Published: (2022-07-01) -
SGLT2 Inhibitors: Nephroprotective Efficacy and Side Effects
by: Carlo Garofalo, et al.
Published: (2019-06-01) -
Efficacy and safety of SGLT2 inhibitors in nondiabetic patients with CKD: a review of recent evidence
by: Junhao Lv, et al.
Published: (2023-04-01) -
SGLT2 Inhibitors for Cardioprotection
by: Sulthan Al Rashid, et al.
Published: (2023-07-01)